Stockscreener 앱 받기
25.93
7.46%
1.80
시간 외 거래:
25.95
0.02
+0.08%
전일 마감가:
$24.13
열려 있는:
$24.13
하루 거래량:
815.96K
Relative Volume:
2.68
시가총액:
$1.16B
수익:
$45.95M
순이익/손실:
$-48.88M
주가수익비율:
-23.30
EPS:
-1.1129
순현금흐름:
$109.67M
1주 성능:
+5.88%
1개월 성능:
+3.14%
6개월 성능:
+11.14%
1년 성능:
+312.24%
1일 변동 폭
$23.31
$25.99
1주일 범위
$22.83
$25.99
52주 변동 폭
$5.73
$32.63
Septerna Inc Stock (SEPN) Company Profile
명칭
Septerna Inc
전화
650-338-3533
주소
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Compare SEPN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
25.93 | 1.08B | 45.95M | -48.88M | 109.67M | -1.1129 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-19 | 개시 | Raymond James | Strong Buy |
| 2025-12-15 | 개시 | Truist | Buy |
| 2025-11-14 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-06-23 | 개시 | H.C. Wainwright | Buy |
| 2025-02-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-11-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-11-19 | 개시 | JP Morgan | Overweight |
| 2024-11-19 | 개시 | TD Cowen | Buy |
| 2024-11-19 | 개시 | Wells Fargo | Overweight |
모두보기
Septerna Inc 주식(SEPN)의 최신 뉴스
Septerna (SEPN) price target increased by 34.39% to 46.41 - MSN
SEPN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Septerna: Advancing GPCR Pipeline and Strategic Partnerships Support Buy Rating and $40 Price Target - TipRanks
Is Septerna (SEPN) Using Its First PTH1R Trial To Redefine Its GPCR Strategy? - Sahm
H.C. Wainwright reiterates Septerna stock rating on trial start By Investing.com - Investing.com South Africa
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism - Bitget
SEPTERNA INCPHASE 1 TRIAL DATA EXPECTED IN LATE 2026 OR EARLY 2027 - Moomoo
Septerna doses first patient in SEP-479 hypoparathyroidism trial By Investing.com - Investing.com Australia
Insider Buy: Is Septerna Inc part of any ETF2026 Sector Review & Risk Controlled Stock Alerts - baoquankhu1.vn
Septerna (SEPN) Initiates Phase 1 Trial for Hypoparathyroidism T - GuruFocus
Movement Recap: Will Septerna Inc benefit from current market trendsWeekly Loss Report & Accurate Buy Signal Notifications - baoquankhu1.vn
Septerna Begins Phase 1 Clinical Trial of SEP-479, an Oral PTH1R Agonist, for Hypoparathyroidism Treatment – Data Expected Late 2026/Early 2027 1 - Minichart
Septerna Begins Phase 1 Trial of Oral SEP-479 - TipRanks
Septerna doses first patient in SEP-479 hypoparathyroidism trial - Investing.com
Septerna begins Phase 1 trial of oral PTH1R agonist SEP-479; Phase 1 data expected late 2026–early 2027 - TradingView — Track All Markets
Septerna (Nasdaq: SEPN) begins Phase 1 trial of SEP-479 for hypoparathyroidism - Stock Titan
Septerna starts human testing of an oral drug for a lifelong disorder - Stock Titan
Buyout Rumor: How does Septerna Inc correlate with NasdaqEarnings Beat & Real-Time Volume Analysis - baoquankhu1.vn
FOMO Trade: Is Septerna Inc part of any ETF2026 Technical Overview & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Will Septerna Inc benefit from current market trends2026 Price Momentum & Weekly High Conviction Ideas - baoquankhu1.vn
SEPN: Septerna, Inc.Detailed Earnings Estimates - Zacks Investment Research
Septerna tops Q4 loss expectations as collaboration revenue lifts results - MSN
Septerna, Inc. (NASDAQ:SEPN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
J.P. Morgan Maintains Septerna(SEPN.US) With Buy Rating, Announces Target Price $38 - Moomoo
Septerna (NASDAQ:SEPN) Given New $38.00 Price Target at JPMorgan Chase & Co. - marketbeat.com
JP Morgan Raises Price Target for Septerna (SEPN) to $38 | SEPN Stock News - GuruFocus
Septerna price target raised to $38 from $34 at JPMorgan - TipRanks
Should Septerna’s New ATM and Shelf Offering Strategy Require Action From Septerna (SEPN) Investors? - simplywall.st
Big Picture: How volatile is Septerna Inc stock2026 WrapUp & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Septerna (SEPN) Expected to Announce Earnings on Thursday - MarketBeat
Layoff Watch: Will Septerna Inc outperform the market in YEARTrade Entry Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Septerna (SEPN) Is Down 13.5% After Launching US$150 Million ATM Equity Program and Filing Shelves - simplywall.st
Checkpoint Capital L.P. Trims Stock Position in Septerna, Inc. $SEPN - MarketBeat
Avoro Capital Advisors LLC Grows Stock Holdings in Septerna, Inc. $SEPN - MarketBeat
Septerna (NASDAQ:SEPN) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
HC Wainwright Has Negative Outlook for Septerna Q1 Earnings - MarketBeat
What is HC Wainwright's Forecast for Septerna Q1 Earnings? - MarketBeat
Analysts Conflicted on These Technology Names: Fortinet (FTNT), Septerna, Inc. (SEPN) and Oracle (ORCL) - The Globe and Mail
Truist Financial Forecasts Strong Price Appreciation for Septerna (NASDAQ:SEPN) Stock - MarketBeat
Septerna (SEPN) Q4 Loss Despite Revenue Surge Reinforces Bearish Profitability Narrative - simplywall.st
Wells Fargo Reaffirms Their Buy Rating on Septerna, Inc. (SEPN) - The Globe and Mail
Truist Lifts Price Target on Septerna to $35 From $34, Keeps Buy Rating - marketscreener.com
Cantor Fitzgerald Maintains Overweight on Septerna, Inc. (SEPN) March 2026 - Meyka
Truist raises Septerna stock price target to $35 on trial progress - Investing.com
Cantor Fitzgerald reiterates Septerna stock rating on platform value By Investing.com - Investing.com Australia
Cantor Fitzgerald reiterates Septerna stock rating on platform value - Investing.com
Septerna Inc (SEPN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):